Sign in
CUBT Stock Price, Chart, Stats & News
Curative Biotechnology, Inc.
Save
Curative Biotechnology, Inc. (CUBT) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
CUBT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -99.20% |
ROE | 47.24% |
D/E | -0.62x |
Interest coverage ratio | -1.66x |
CUBT valuation
P/E | – |
P/S | – |
P/B | -2.23x |
P/CF | -12.63x |
P/FCF | -14.54x |
P/OCF | -12.63x |
PEG | 1.42x |
EV multiple | -7.35x |
About
Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused on developing pharmaceutical products. Its research and development efforts are concentrated on a diverse pipeline targeting critical therapeutic areas, including infectious diseases, cancer, and vision-impairing degenerative eye conditions. Among its key pipeline assets is IMT504, an innovative immunotherapy designed for rabies treatment and as a vaccine enhancer.
Similar securities
Based on sector and market capitalization
Report issue